What Is Pliant Therapeutics, Inc. (PLRX) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Pliant Therapeutics, Inc.'s intrinsic value is estimated at $1.54, suggesting a +37.5% average upside from the current price of $1.12. While 4 models see room for appreciation, model agreement is not unanimous as 3 models flag potential overvaluation. Model dispersion is worth noting: Dynamic NAV targets $3.52 (+214.4%), versus Bayesian DCF at $0.04 (-96.6%). This +311.0% range highlights the importance of multi-model analysis rather than relying on any single methodology.
What Do the Models Say About PLRX?
7 of 13 models are currently active for PLRX. Of these, 4 models suggest upside while 3 models suggest overvaluation. The Bayesian DCF estimates PLRX's intrinsic value at $0.04, implying -96.6% downside from the current price. See which stocks rank higher →
How Does PLRX Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, PLRX ranks #206 by Quality of Company score. CirclFi's QOC score of 5.0/10 evaluates 32 fundamental signals. A score of 5.0 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
The Pharmaceutical Preparations sector introduces analytical considerations specific to biopharma enterprise businesses. For Pliant Therapeutics, Inc., metrics like clinical trial success rate provide important context that general-purpose valuation models may underweight.
Is PLRX a Value Trap?
CirclFi's Value Trap algorithm assigns PLRX a score of 26/100 (LOW). This indicates low risk. The financial profile does not exhibit typical value trap warning signs. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
7 of 13 models are active for Pliant Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi Deep Alpha Valuation Engine, Pliant Therapeutics, Inc. scores 5.0 out of 10 on our 32-signal quality assessment, a moderate rating that shows mixed signals across our quality framework with notable weaknesses. The QOC score synthesizes profitability margins, revenue growth reliability, debt management, and capital allocation into a single metric designed to separate durable businesses from statistically cheap ones.
The gap between the most bullish and bearish model spans +311.0% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PLRX valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PLRX's 7 active models, average confidence is 26%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad